KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Interest Expenses (2019 - 2025)

Esperion Therapeutics (ESPR) has disclosed Interest Expenses for 7 consecutive years, with $22.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses rose 37.84% year-over-year to $22.6 million, compared with a TTM value of $84.6 million through Dec 2025, up 42.79%, and an annual FY2025 reading of $84.6 million, up 42.79% over the prior year.
  • Interest Expenses was $22.6 million for Q4 2025 at Esperion Therapeutics, up from $22.1 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $22.6 million in Q4 2025 and bottomed at $8.1 million in Q1 2021.
  • Average Interest Expenses over 5 years is $15.3 million, with a median of $14.4 million recorded in 2022.
  • The sharpest move saw Interest Expenses skyrocketed 177.07% in 2021, then dropped 5.6% in 2024.
  • Year by year, Interest Expenses stood at $13.4 million in 2021, then grew by 6.69% to $14.3 million in 2022, then grew by 5.08% to $15.1 million in 2023, then rose by 9.07% to $16.4 million in 2024, then surged by 37.84% to $22.6 million in 2025.
  • Business Quant data shows Interest Expenses for ESPR at $22.6 million in Q4 2025, $22.1 million in Q3 2025, and $20.5 million in Q2 2025.